Alcobra Ltd. to Participate in Upcoming Investment Conferences

TEL AVIV, Israel, June 01, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome (Fragile X), today announced corporate presentations at the upcoming Jefferies 2016 Healthcare Conference and the ROTH 3rd Annual Healthcare Day.

Jefferies 2016 Healthcare Conference
Date: Wednesday, June 8
Time: 8:00am Eastern Daylight Time
Location: Grand Hyatt Hotel, New York City
ROTH 3rd Annual Healthcare Day
Date: Wednesday, June 22
Location: The Dorchester Hotel, London UK

About Alcobra Ltd.
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of MDX, a proprietary drug candidate, to treat cognitive disorders including ADHD and Fragile X. For more information please visit the Company's website,, the content of which is not incorporated herein by reference.

U.S. Investor Contacts LifeSci Advisors, LLC Michael Rice 646-597-6979 Media Inquiries Sam Brown, Inc. Mike Beyer 773-463-4211 Israel Investor Contact: Alcobra Investor Relations Debbie Kaye +972-72 2204661

Source:Alcobra Ltd.